{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:40:35Z","timestamp":1778902835271,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s13730-017-0277-y","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:30:58Z","timestamp":1507595458000},"page":"210-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enzyme replacement therapy in a patient of heterozygous Fabry disease: clinical and pathological evaluations by repeat kidney biopsy and a successful pregnancy"],"prefix":"10.1007","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-0475","authenticated-orcid":false,"given":"Yoichi","family":"Iwafuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiko","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"277_CR1","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited diseases","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited diseases, 8th edn. New York: McGraw-Hill; 2001. pp.\u00a03733\u201374.","edition":"8"},{"key":"277_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, T\u00f8ndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"key":"277_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","volume":"91","author":"R Schiffmann","year":"2017","unstructured":"Schiffmann R, Hughes DA, Linthorst GE, Ortiz A, Svarstad E, Warnock DG, West ML, Wanner C. Conference participants. screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. 2017;91:284\u201393.","journal-title":"Kidney Int"},{"key":"277_CR4","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Mar\u00f3di L, Mignani R, Vujkovac B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C, Fabry Registry. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transpl. 2012;27:1042\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"277_CR5","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O\u2019Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62:1933\u201346.","journal-title":"Kidney Int"},{"key":"277_CR6","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"277_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2012030316","volume":"24","author":"C T\u00f8ndel","year":"2013","unstructured":"T\u00f8ndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24:137 \u2013 48.","journal-title":"J Am Soc Nephrol"},{"key":"277_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/humu.22910","volume":"37","author":"J Lukas","year":"2016","unstructured":"Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C, Giese AK, Rolfs A. Functional and clinical consequences of novel \u03b1-galactosidase A mutations in Fabry disease. Hum Mutat. 2016;37:43\u201351.","journal-title":"Hum Mutat"},{"key":"277_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","volume":"121","author":"A Nowak","year":"2017","unstructured":"Nowak A, Mechtler T, Kasper DC, Desnick RJ. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease. Mol Genet Metab. 2017;121:320\u20134.","journal-title":"Mol Genet Metab"},{"key":"277_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000369309","volume":"129","author":"C T\u00f8ndel","year":"2015","unstructured":"T\u00f8ndel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron. 2015;129:16\u201321.","journal-title":"Nephron"},{"key":"277_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-1172-4-21","volume":"4","author":"B Hoffmann","year":"2009","unstructured":"Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21.","journal-title":"Orphanet J Rare Dis"},{"key":"277_CR12","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s00467-016-3387-4","volume":"31","author":"S Ito","year":"2016","unstructured":"Ito S, Ogura M, Kamei K, Matsuoka K, Warnock DG. Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta. Pediatr Nephrol. 2016;31:1369\u201373.","journal-title":"Pediatr Nephrol"},{"key":"277_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10545-005-0018-9","volume":"28","author":"S Wendt","year":"2005","unstructured":"Wendt S, Whybra C, Kampmann C, Teichmann E, Beck M. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis. 2005;28:787\u20138.","journal-title":"J Inherit Metab Dis"},{"key":"277_CR14","first-page":"406","volume":"9","author":"E Senocak Tasci","year":"2015","unstructured":"Senocak Tasci E, Bicik Z. Safe and successful treatment with agalsidase beta during pregnancy in Fabry disease. Iran J Kidney Dis. 2015;9:406\u20138.","journal-title":"Iran J Kidney Dis"},{"key":"277_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1126\/science.172.3979.174","volume":"172","author":"RO Brady","year":"1971","unstructured":"Brady RO, Uhlendorf BW, Jacobson CB. Fabry\u2019s disease: antenatal detection. Science. 1971;172:174\u20135.","journal-title":"Science"},{"key":"277_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10545-006-0196-0","volume":"29","author":"AC Vedder","year":"2006","unstructured":"Vedder AC, Strijland A, vd Bergh Weerman MA, Florquin S, Aerts JM, Hollak CE. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis. 2006;29:106 \u2013 11.","journal-title":"J Inherit Metab Dis"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-017-0277-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-017-0277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-017-0277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T09:38:46Z","timestamp":1567762726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-017-0277-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1007\/s13730-017-0277-y","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]},"assertion":[{"value":"7 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"H. M. has received speaker fees, research support from Sanofi. I. N. has received donations for research from Sanofi and Sumitomo Dainippon Pharm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}